tradingkey.logo

Metagenomi Inc

MGX
查看詳細走勢圖
1.540USD
+0.130+9.22%
收盤 02/06, 16:00美東報價延遲15分鐘
57.82M總市值
虧損本益比TTM

Metagenomi Inc

1.540
+0.130+9.22%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+9.22%

5天

0.00%

1月

-11.49%

6月

-26.67%

今年開始到現在

-4.94%

1年

-41.67%

查看詳細走勢圖

TradingKey Metagenomi Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Metagenomi Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業中等水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名113/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為9.33。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Metagenomi Inc評分

相關信息

行業排名
113 / 392
全市場排名
246 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Metagenomi Inc亮點

亮點風險
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
業績高增長
公司營業收入穩步增長,連續3年增長204.04%
業績增長期
公司處於發展階段,最新年度總收入52.30M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入52.30M美元
估值高估
公司最新PE估值-0.64,處於3年歷史高位
機構減倉
最新機構持股6.70M股,環比減少56.89%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉1.27M股

分析師目標

基於 5 分析師
買入
評級
9.333
目標均價
+561.94%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Metagenomi Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Metagenomi Inc簡介

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
公司代碼MGX
公司Metagenomi Inc
CEOIrish (Jian)
網址https://metagenomi.co/
KeyAI